Dual-Orexin Antagonism as a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

Dual-Orexin Antagonism as a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

Publication date: Feb 10, 2020

Summary of Study Protocol. This project is designed to test neurobehavioral mechanisms underlying effects of the dual orexin-1/2 receptor antagonist suvorexant on sleep efficiency and opioid abstinence, and whether these outcomes are independent of one another. This will be the first study to investigate whether suvorexant improves outpatient opioid abstinence and sleep efficiency; and whether improving sleep mediates the improved opioid abstinence outcome. 180 participants with opioid use disorder (OUD) who have just completed detoxification will complete this intent-to-treat study.

Concepts Keywords
Abstinence Suvorexant
Agonist Orexin
Alcohol Buprenorphine
Analgesics Insomnia
Antagonist Morphinans
Anticonvulsants Morphine
Antidepressants Euphoriants
Antihistamines Drug rehabilitation
Anxiolytics Opioids
Apnea Psychoactive drugs
Arousal RTT
Bipolar Disorder Nicotine replacement therapy
Birth Control Birth control
Buprenorphine Apnea
Circadian Criteria opioid disorder
Circadian Rhythm Acute unstable illness
Comorbid Depression
Decongestants Withdrawal symptoms
Depression Chronic illnesses
Detoxification Parallel
DSM Sleep disordered breathing
EEG
Hypnotics
Internal Validity
Liver Disease
Loperamide
Methadone
Narcolepsy
Narcotic
Nicotine Replacement Therapy
Opioid
Opioids
Orexin
Pain
Placebo
PLM
Psychosis
PTSD
Randomized Clinical Trial
Receptor
Renal Failure
Respiratory Infection
Restless Legs Syndrome
Sedating
Seizures
Shift Work
Sleep
Sleep Loss
Steroids
Stimulants
Stratification
Withdrawal Symptoms

Semantics

Type Source Name
drug DRUGBANK Nicotine
disease MESH bipolar disorder
disease MESH PTSD
disease MESH Sleep
drug DRUGBANK Suvorexant
disease MESH infection
disease MESH Chronic illnesses
disease MESH renal failure
disease MESH liver disease
disease MESH seizures
disease MESH psychiatric disease
disease MESH psychosis
drug DRUGBANK Loperamide
disease MESH withdrawal symptoms
drug DRUGBANK Buprenorphine
drug DRUGBANK Methadone
pathway KEGG Circadian rhythm
disease MESH Substance-Related Disorders
disease MESH restless legs syndrome
disease MESH narcolepsy
drug DRUGBANK Hexadecanal
disease MESH aids
disease MESH Sleep-disordered breathing

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *